Dupont Jakob 4

What Happened
Dupont Jakob, a director of Bolt Biotherapeutics, was granted a derivative award covering 5,000 shares on 2026-06-10. The Form 4 reports the acquisition as a derivative award at $0.00 (total value reported $0), indicating an option/award grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-11 (timely filing).
• Reported transaction: Award/derivative acquisition of 5,000 shares; acquisition price shown as $0.00 on the Form 4.
• Vesting (per footnote): vests on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting, subject to continuous service; vests in full upon a change in control.
• Shares owned after the transaction: not stated in the provided excerpt.
• No 10b5-1 plan, tax withholding sale, or late filing indicated in the information supplied.

Context
This transaction is an equity award/option grant to a director. Unlike an open-market purchase or sale, an option grant does not represent an immediate cash investment or divestment — it creates a right to acquire shares if vesting and any exercise conditions are met. The Form 4 shows $0 for the reported acquisition amount; the actual exercise price or other award terms (if any) are not detailed in the excerpt beyond the vesting schedule.